A Novel Semi-biosynthetic Route for Artemisinin Production Using Engineered Substrate-Promiscuous P450 <sub>BM3</sub>

Jeffrey A. Dietrich(Lawrence Berkeley National Laboratory), Yasuo Yoshikuni(Howard Hughes Medical Institute), Karl J. Fisher(Amyris (United States)), Frank X. Woolard(Amyris (United States)), Denise A. Ockey(Amyris (United States)), Derek McPhee(Amyris (United States)), Neil S. Renninger(Amyris (United States)), Michelle C. Y. Chang(Lawrence Berkeley National Laboratory), David Baker(Howard Hughes Medical Institute), Jay D. Keasling(QB3)
ACS Chemical Biology
March 9, 2009
Cited by 186Open Access
Full Text

Abstract

Production of fine chemicals from heterologous pathways in microbial hosts is frequently hindered by insufficient knowledge of the native metabolic pathway and its cognate enzymes; often the pathway is unresolved, and the enzymes lack detailed characterization. An alternative paradigm to using native pathways is de novo pathway design using well-characterized, substrate-promiscuous enzymes. We demonstrate this concept using P450(BM3) from Bacillus megaterium. Using a computer model, we illustrate how key P450(BM3) active site mutations enable binding of the non-native substrate amorphadiene. Incorporating these mutations into P450(BM3) enabled the selective oxidation of amorphadiene artemisinic-11S,12-epoxide, at titers of 250 mg L(-1) in E. coli. We also demonstrate high-yielding, selective transformations to dihydroartemisinic acid, the immediate precursor to the high-value antimalarial drug artemisinin.


Related Papers

No related papers found

Powered by citation graph analysis